Loading organizations...
Pearl Street Venture Funds operates as a venture capital firm primarily focused on investing in early-stage life sciences companies. The firm employs an operator-led and execution-driven approach, designed to support innovative entrepreneurs by providing strategic capital and guidance. Its core capabilities center on identifying promising early-stage ventures within the healthcare and biotechnology sectors.
The fund was established in 2004, arising from a partnership between Barnard Associates and Coastview Capital to co-manage the venture. John H. Barnard is noted as a key figure in the firm's inception, contributing to its foundation as a platform dedicated to the life sciences. The insight driving its formation was the recognition of a need for specialized early-stage investment and operational support within this complex industry.
Pearl Street Venture Funds' portfolio companies are early-stage innovators in life sciences, benefiting from its active, hands-on investment style. The firm’s mission is to empower these emerging companies to develop solutions that advance healthcare. Pearl Street Venture Funds aims to contribute to the growth of impactful life science technologies and businesses, fostering progress within the sector.
Pearl Street Venture Funds has 2 tracked investments across 1 company. The latest tracked deal is $37.0M Series C in CoLucid Pharmaceuticals in January 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2015 | CoLucid Pharmaceuticals | $37.0M Series C | DR. LUC Marengere | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures, Auriga Partners, Care Capital, Martin Edwards, Pappas Ventures, Triathlon Medical Ventures |
| Aug 30, 2011 | CoLucid Pharmaceuticals | $7.5M Other Equity | — | Care Capital, Domain Associates, ART Pappas, Triathlon Medical Ventures |
